Comparative treatment costs of risk-stratified therapy for childhood acute lymphoblastic leukemia in India.

ABSTRACT:

Background

To evaluate the treatment cost and cost effectiveness of a risk-stratified therapy to treat pediatric acute lymphoblastic leukemia (ALL) in India.

Methods

The cost of total treatment duration was calculated for a retrospective cohort of ALL children treated at a tertiary care facility. Children were risk stratified into standard (SR), intermediate (IR) and high (HR) for B-cell precursor ALL, and T-ALL. Cost of therapy was obtained from the hospital electronic billing systems and details of outpatient (OP) and inpatient (IP) from electronic medical records. Cost effectiveness was calculated in disability-adjusted life years.

Results

One hundred and forty five patients, SR (50), IR (36), HR (39), and T-ALL (20) were analyzed. Median cost of the entire treatme

SUBMITTER: Mungle T 

PROVIDER: S-EPMC9939102 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature